Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
CONJUGATES OF AMPK INHIBITORS AND PROTAC DEGRADERS AND RELATED USES
Document Type and Number:
WIPO Patent Application WO/2022/006412
Kind Code:
A3
Abstract:
The present disclosure relates to compounds of Formula (I): T-L-D, stereoisomers thereof, prodrugs thereof, and pharmaceutically acceptable salts thereof, wherein T is an AMPK inhibiting moiety; L is a linking moiety; and D is a PROTAC degrading moiety. The present disclosure also relates to uses of the compounds, e.g., to inhibit AMP-Activated protein kinase (AMPK), degrading AMPK protein, and/or treat cancer in a subject.

Inventors:
REIGAN PHILIP (US)
MATHESON CHRISTOPHER (GB)
Application Number:
PCT/US2021/040113
Publication Date:
February 03, 2022
Filing Date:
July 01, 2021
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
UNIV COLORADO REGENTS (US)
REIGAN PHILIP (US)
MATHESON CHRISTOPHER (GB)
International Classes:
C07D401/14; A61K31/404; A61K47/55; A61P35/00
Domestic Patent References:
WO2018098280A12018-05-31
WO2008033562A22008-03-20
WO2000008202A22000-02-17
Other References:
KEITH R. LADEROUTE ET AL: "SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK)", CANCER BIOLOGY & THERAPY 10:1, 1-8; JULY 1, 2010, 1 July 2010 (2010-07-01), XP055852171, Retrieved from the Internet [retrieved on 20211018]
Attorney, Agent or Firm:
PAVAO, Matthew et al. (US)
Download PDF: